Silvia Luque announced on LinkedIn that she has been named head of US marketing at Zealand Pharma after 13 years at Eli Lilly. A biotech news report published July 17, 2026, also notes that Bexorg has hired a chief scientific officer from Biohaven, though full details are behind a paywall. The…
Silvia Luque has announced via LinkedIn that she is taking on the role of head of US marketing at Zealand Pharma. This move comes after a 13-year tenure at Eli Lilly, where she presumably held marketing positions. The announcement was made public on the professional networking platform. Zealand Pharma is a biotechnology company focused on peptide-based therapies, though the specific responsibilities of Luque’s new role were not detailed in the report preview.
In another executive hire covered in the same report, Bexorg has turned to Biohaven for its next chief scientific officer. The article headline explicitly states that Bexorg is bringing in a CSO from Biohaven. However, the full body of the article behind the paywall likely contains additional details such as the executive's name and background. Without access to the complete text, no further specifics are available for non-subscribers.
The article's headline highlights two significant executive moves: Zealand Pharma acquiring its US marketing leader from Lilly, and Bexorg turning to Biohaven for a CSO hire. While the preview provides only a snippet about Luque, the headline indicates that both stories are covered in the full piece. This dual focus gives readers a snapshot of recent talent movements in the biotech industry, though the completeness of the information depends on subscription status.
Related reading: Inside Medicare's New GLP-1 Bridge Program for Weight Loss, NBC News Asks If Stopping GLP-1 Means Full Weight Regain, GLP-1 Drugs May Cut Overdose Risk, Benefit May Last After Stopping, European Commission Approves Wegovy Oral Tablet for Weight Loss.